NuCana plc
Records under this name other than the patents NuCana plc holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 26 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,662,213 | Gemcitabine prodrugs Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,570,168 | 2' And/Or 5' Amino-Acid Ester Phosphoramidate 3'-Deoxy Adenosine Derivatives as Anti-Cancer Compounds Formerly held In force · High confidence | In force | High confidence | |
| US RE47,589 | Phosphoramidate compounds and methods of use Term ended Term ended Jul 25, 2026 · From the USPTO record | Term ended | Term ended Jul 25, 2026 | From the USPTO record |
| US 11,377,467 | Crystalline Form of Gemcitabine Lapsed on the fee record Ended Jul 5, 2026 · High confidence | Lapsed on the fee record | Ended Jul 5, 2026 | High confidence |
| US 9,834,577 | Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate Lapsed on the fee record Ended Dec 5, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 5, 2025 | From the USPTO record |
| US 11,040,051 | Formulation comprising a gemcitabine-prodrug Lapsed on the fee record Ended Jun 22, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 22, 2025 | From the USPTO record |
| US 10,906,929 | Phosphoramidate nucleoside derivatives as anticancer agents Lapsed on the fee record Ended Feb 2, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 2, 2025 | From the USPTO record |
| US 10,774,104 | Diastereoselective Synthesis of Phosphate Derivatives Lapsed on the fee record Ended Sep 15, 2024 · High confidence | Lapsed on the fee record | Ended Sep 15, 2024 | High confidence |
| US 8,263,575 | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer Lapsed on the fee record Ended Sep 11, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 11, 2024 | From the USPTO record |
| US 9,321,798 | Phosphoramidite derivatives of gemcitabine for use in the treatment of cancer Lapsed on the fee record Ended Apr 26, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 26, 2024 | From the USPTO record |